Cerenome (PSTV) Receivables - Net (2010 - 2026)

Plus Therapeutics (PSTV) posted quarterly Receivables - Net of $1.3 million for Q1 2026, up 319.25% quarter-over-quarter from $322000.0 in Q4 2025.

Cerenome (PSTV) Receivables - Net (2010 - 2026) Analysis & Trends

Plus Therapeutics (PSTV) has reported Receivables - Net for 16 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables - Net changed N/A year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $322000.0, down 43.61% from the prior year.
Receivables - Net rose to $1.3 million in Q1 2026 per PSTV's latest filing, from $322000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $1.3 million in Q1 2026 and bottomed at $73000.0 in Q3 2022.
Historically, Receivables - Net has averaged $592285.7 across 5 years, with a median of $571000.0 in 2024.
Annual changes were most pronounced in 2023 — Receivables - Net climbed 24.66% — and 2025, when it plunged 43.61%.
Plus Therapeutics' Receivables - Net stood at $73000.0 in 2022, then climbed by 24.66% to $91000.0 in 2023, then surged by 527.47% to $571000.0 in 2024, then slumped by 43.61% to $322000.0 in 2025, then jumped by 319.25% to $1.3 million in 2026.
Business Quant data shows PSTV's Receivables - Net at $1.3 million in Q1 2026, $322000.0 in Q4 2025, and $1.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-
10	Cerenome	28.07 Mn	19.48 Mn	-

Download Data